{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:28:36Z","timestamp":1768321716565,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81,903,717"],"award-info":[{"award-number":["81,903,717"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejps.2020.105584","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:48:43Z","timestamp":1602204523000},"page":"105584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Mechanistic prediction of first-in-human dose for bispecific CD3\/EpCAM T-cell engager antibody M701, using an integrated PK\/PD modeling method"],"prefix":"10.1016","volume":"158","author":[{"given":"Ling","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junsheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105584_bib0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2125.2008.03297.x","article-title":"Use of pharmacokinetic\/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics","volume":"67","author":"Agoram","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105584_bib0002","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I\/II study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2020.105584_bib0003","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1158\/1078-0432.CCR-17-2265","article-title":"Integrated Pharmacokinetic\/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: evaluation of Activity and Impact of Immunogenicity","volume":"24","author":"Campagne","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2020.105584_bib0004","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/cpt.393","article-title":"Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: an Integrated PK\/PD Modeling Approach","volume":"100","author":"Chen","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105584_bib0008","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/clpt.2008.158","article-title":"Safety issues specific to clinical development of protein therapeutics","volume":"84","author":"Haller","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105584_bib0009","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.ejps.2020.105584_bib0010","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00262-010-0894-1","article-title":"Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action","volume":"59","author":"Hirschhaeuser","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejps.2020.105584_bib0011","doi-asserted-by":"crossref","unstructured":"Hodge, C., Badgwell, B.D., 2019. Palliation of malignant ascites. 120, 67\u201373. 10.1002\/jso.25453.","DOI":"10.1002\/jso.25453"},{"key":"10.1016\/j.ejps.2020.105584_bib0012","first-page":"1771","article-title":"Functions of EpCAM in physiological processes and diseases (Review)","volume":"42","author":"Huang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejps.2020.105584_bib0013","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/19420862.2018.1480299","article-title":"Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents","volume":"10","author":"Jiang","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2020.105584_bib0014","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1124\/dmd.114.059121","article-title":"Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins","volume":"42","author":"Kagan","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2020.105584_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2016.09.004","article-title":"Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies","volume":"21-22","author":"Kamath","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejps.2020.105584_bib0016","article-title":"Management of drainage for malignant ascites in gynaecological cancer","volume":"12","author":"Kietpeerakool","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejps.2020.105584_bib0017","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","article-title":"Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer","volume":"119","author":"Knodler","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejps.2020.105584_bib0018","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1177\/0091270009337134","article-title":"Interspecies scaling of therapeutic monoclonal antibodies: initial look","volume":"49","author":"Ling","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105584_bib0019","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.copbio.2009.10.013","article-title":"The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies","volume":"20","author":"Muller","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejps.2020.105584_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-1759(03)00002-4","article-title":"Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells","volume":"275","author":"Nguyen","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejps.2020.105584_bib0021","first-page":"330","article-title":"The diagnostic work-up in patients with ascites: current guidelines and future prospects","volume":"74","author":"Oey","year":"2016","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.ejps.2020.105584_bib0022","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2133\/dmpk.DMPK-11-RG-011","article-title":"Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data","volume":"26","author":"Oitate","year":"2011","journal-title":"Drug Metab. Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105584_bib0023","doi-asserted-by":"crossref","unstructured":"Ross, S.L.; Sherman, M.; McElroy, P.L.; Lofgren, J.A.; Moody, G.; Baeuerle, P.A.; Coxon, A.; Arvedson, T., Bispecific T cell engager (BiTE(R)) antibody constructs can mediate bystander tumor cell killing. 12 (2017) e0183390. 10.1371\/journal.pone.0183390.","DOI":"10.1371\/journal.pone.0183390"},{"key":"10.1016\/j.ejps.2020.105584_bib0024","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.2010.03635.x","article-title":"Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients","volume":"69","author":"Ruf","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105584_bib0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.yrtph.2017.09.001","article-title":"An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection","volume":"90","author":"Saber","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105584_bib0026","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.yrtph.2016.10.002","article-title":"An FDA oncology analysis of immune activating products and first-in-human dose selection","volume":"81","author":"Saber","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105584_bib0027","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12885-015-1371-1","article-title":"Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro","volume":"15","author":"Seeber","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejps.2020.105584_bib0028","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41598-018-19384-0","article-title":"Exclusion from spheroid formation identifies loss of essential cell-cell adhesion molecules in colon cancer cells","volume":"8","author":"Stadler","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2020.105584_bib0029","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s13402-018-0399-z","article-title":"Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma","volume":"41","author":"Sun","year":"2018","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.ejps.2020.105584_bib0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2217\/pme-2017-0071","article-title":"Effects of immuno-related gene polymorphisms on a bispecific antibody targeting colorectal cancer cell","volume":"15","author":"Zhang","year":"2018","journal-title":"Per. Med."},{"key":"10.1016\/j.ejps.2020.105584_bib0031","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/dna.2017.3962","article-title":"APTM, a Thiophene Heterocyclic Compound, Inhibits Human Colon Cancer HCT116 Cell Proliferation Through p53-Dependent Induction of Apoptosis","volume":"37","author":"Liao","year":"2018","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.ejps.2020.105584_bib0033","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cyto.b.21171","article-title":"A new flow cytometric method for differential cell counting in ascitic fluid","volume":"90","author":"van de Geijn","year":"2016","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.ejps.2020.105584_bib0034","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2013-03-488411","article-title":"Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans","volume":"122","author":"Westera","year":"2013","journal-title":"BloodBlood"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720303729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720303729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:56:20Z","timestamp":1760529380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720303729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"alternative-id":["S0928098720303729"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105584","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic prediction of first-in-human dose for bispecific CD3\/EpCAM T-cell engager antibody M701, using an integrated PK\/PD modeling method","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105584"}}